These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38787493)

  • 1. Clinical Characteristics and Outcomes of Pembrolizumab Induced Gastritis: A Systematic Review of the Literature.
    Lei H; Sun W; Liu X; Wang C
    J Gastrointest Cancer; 2024 Sep; 55(3):1-8. PubMed ID: 38787493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis.
    Lei H; Sun W; Liu X; Wang C
    Invest New Drugs; 2024 Feb; 42(1):53-59. PubMed ID: 38063991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual severe gastritis and gastric ulcers caused by pembrolizumab.
    Liu WT; Li YF; Hsieh TY
    J Postgrad Med; 2022; 68(1):38-40. PubMed ID: 34121670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
    Rao BB; Robertson S; Philpott J
    Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pembrolizumab-induced gastritis with PDL1 histological expression].
    Nicolini C; Manzano N; Flagel S; Sánchez C; García X; Coliva G; Pombo T; Zylberman M
    Medicina (B Aires); 2023; 83(6):994-997. PubMed ID: 38117721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal observation of endoscopic and histological findings of gastritis after administration of an immune checkpoint inhibitor: a case report.
    Saito K; Ozono D; Nagumo H; Yoshimura M; Masuzawa Y
    Clin J Gastroenterol; 2022 Apr; 15(2):368-373. PubMed ID: 34985687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodular gastritis in adults: clinical features, endoscopic appearance, histopathological features, and response to therapy.
    Dwivedi M; Misra SP; Misra V
    J Gastroenterol Hepatol; 2008 Jun; 23(6):943-7. PubMed ID: 17614956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis.
    Johncilla M; Grover S; Zhang X; Jain D; Srivastava A
    Histopathology; 2020 Mar; 76(4):531-539. PubMed ID: 31692018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis.
    Luo P; Guo Y; He Y; Wang C
    Invest New Drugs; 2024 Aug; 42(4):369-375. PubMed ID: 38829427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab - Differences and Similarities in Comparison to "endogenous" autoimmune Type A Gastritis and a review of literature.
    Ecker ME; Weckauf H; Tebbe S; Schuppert F
    Z Gastroenterol; 2023 Oct; 61(10):1385-1393. PubMed ID: 36963423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes.
    Nasser SC; Slim M; Nassif JG; Nasser SM
    World J Gastroenterol; 2015 Apr; 21(15):4599-606. PubMed ID: 25914469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features, treatment, and outcome of pembrolizumab induced cholangitis.
    Fang W; Sun W; Fang W; Zhang J; Wang C
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Oct; 397(10):7905-7912. PubMed ID: 38748225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal: Severe gastritis with complete gastric mucosal sloughing.
    Nasser R; Fisher Y; Klein A
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2639. PubMed ID: 33624341
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy.
    Gaffuri P; Espeli V; Fulciniti F; Paone G; Bergmann M
    Pathologica; 2019 Sep; 111(3):92-97. PubMed ID: 31748755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of proton pump inhibitors on the gastric mucosal microenvironment.
    Peng YC; Huang LR; Ho HC; Chang CS; Lee SW; Cheng CC; Wen MC; Yeh HZ; Ho SP
    Adv Clin Exp Med; 2017; 26(1):39-43. PubMed ID: 28397430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
    Ai Q; Chen W; Li Y; Li G
    Front Immunol; 2022; 13():840916. PubMed ID: 35720298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
    Bello E; Cohen JV; Mino-Kenudson M; Dougan M
    J Immunother Cancer; 2019 Feb; 7(1):41. PubMed ID: 30744698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient.
    Vandepapelière J; Siplet J; Libbrecht L; Dano H; Baurain JF; Moreels T
    Acta Gastroenterol Belg; 2020; 83(3):482-484. PubMed ID: 33094598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.